KR20230074536A - 약제학적 제형 - Google Patents

약제학적 제형 Download PDF

Info

Publication number
KR20230074536A
KR20230074536A KR1020237013787A KR20237013787A KR20230074536A KR 20230074536 A KR20230074536 A KR 20230074536A KR 1020237013787 A KR1020237013787 A KR 1020237013787A KR 20237013787 A KR20237013787 A KR 20237013787A KR 20230074536 A KR20230074536 A KR 20230074536A
Authority
KR
South Korea
Prior art keywords
mitafibat
amount
pediatric subject
pharmaceutically acceptable
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237013787A
Other languages
English (en)
Korean (ko)
Inventor
척-유이 렁
에릭 시몬
오필리아 치핑 인
Original Assignee
아지오스 파마슈티컬스 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아지오스 파마슈티컬스 아이엔씨. filed Critical 아지오스 파마슈티컬스 아이엔씨.
Publication of KR20230074536A publication Critical patent/KR20230074536A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237013787A 2020-09-25 2021-09-24 약제학적 제형 Pending KR20230074536A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063083834P 2020-09-25 2020-09-25
US63/083,834 2020-09-25
US202063107196P 2020-10-29 2020-10-29
US63/107,196 2020-10-29
US202163238483P 2021-08-30 2021-08-30
US63/238,483 2021-08-30
PCT/US2021/051957 WO2022067039A1 (en) 2020-09-25 2021-09-24 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
KR20230074536A true KR20230074536A (ko) 2023-05-30

Family

ID=78179552

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237013787A Pending KR20230074536A (ko) 2020-09-25 2021-09-24 약제학적 제형

Country Status (10)

Country Link
US (1) US20230338283A1 (https=)
EP (1) EP4216956A1 (https=)
JP (1) JP2023542701A (https=)
KR (1) KR20230074536A (https=)
AU (1) AU2021347349A1 (https=)
CA (1) CA3196829A1 (https=)
IL (1) IL301596A (https=)
MX (1) MX2023003431A (https=)
TW (1) TW202228691A (https=)
WO (1) WO2022067039A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2561132C2 (ru) 2009-06-29 2015-08-20 Аджиос Фармасьютикалз, Инк. Производные хинолинсульфонамидов и их применение для модулирования пкм2 активности
FI3307271T3 (fi) 2015-06-11 2023-10-17 Agios Pharmaceuticals Inc Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä
JP7275130B2 (ja) * 2017-11-22 2023-05-17 アジオス ファーマシューティカルズ， インコーポレイテッド Ｎ－（４－（４－（シクロプロピルメチル）ピペラジン－１－カルボニル）フェニル）キノリン－８－スルホンアミドの結晶性形態

Also Published As

Publication number Publication date
US20230338283A1 (en) 2023-10-26
MX2023003431A (es) 2023-05-12
WO2022067039A1 (en) 2022-03-31
CA3196829A1 (en) 2022-03-31
JP2023542701A (ja) 2023-10-11
IL301596A (en) 2023-05-01
TW202228691A (zh) 2022-08-01
AU2021347349A1 (en) 2023-06-08
EP4216956A1 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
Madari et al. Pharmacological management of insomnia
Nance Spinal muscular atrophy
AU2018335259B2 (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
Lechin et al. Neuropharmacologic treatment of bronchial asthma with the antidepressant tianeptine: A double‐blind, crossover placebo‐controlled study
CA2389623A1 (en) Method of treating benign forgetfulness
JP2020535228A (ja) 患者集団中のけいれん発作の数および頻度の低減におけるフェンフルラミン製剤の使用法
EP4005570A1 (en) Use of pridopidine for treating rett syndrome
JP2021523130A (ja) 電位依存性カリウムチャネル開口薬のバイオアベイラビリティー及び曝露を高める方法
CN120379676A (zh) 治疗阿拉杰里综合征(algs)
Aprison et al. Hypersensitive serotonergic receptors: A new hypothesis for one subgroup of unipolar depression derived from an animal model
Breese et al. Model for reduced brain dopamine in Lesch‐Nyhan syndrome and the mentally retarded: Neurobiology of neonatal‐6‐hydroxydopamine‐lesioned rats
KR20230074536A (ko) 약제학적 제형
CN116568281A (zh) 药物制剂
CN107205991A (zh) 增重化合物的组合物及其长期使用方法
Kwinta et al. Pathology and treatment methods in pantothenate kinase-associated neurodegeneration
TW202308630A (zh) 用於滴定米塔皮瓦的方法
WO2019094434A1 (en) Therapeutic combination for treatment of cerebellar ataxia
Ross et al. P1498: initial data from the beacon trial: a phase 2, randomized, open-label trial of bitopertin in erythropoietic protoporphyria
AU2021383325A1 (en) Use of pridopidine and analogs for treating rett syndrome
Hughes et al. Pharmacokinetics and Pharmacodynamics of Levetiracetam in Neonatal Seizures: What We Still Need to Know
US20190247405A1 (en) Treatment of sma
CN117731721B (zh) 植物提取物组合物及其应用
Chesworth et al. Cannabidiol (CBD) does not reduce cocaine reward or self-administration in a mouse model of schizophrenia genetic susceptibility
Wright The Influence Of A Positive Environment On Nicotine Self-Administration. A Gene-Environment Interaction Study
TW202425962A (zh) 用於製備延緩老化及預防老年疾病之組合物的s-烯丙基半胱氨酸之用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230424

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination